Mosunetuzumab for CLL MRD Clearance

The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of the study drugs in this research study are: * Mosunetuzumab * BTK inhibitor: Ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib

Trial Details

NCT ID
NCT07052695
Phase
PHASE1 / PHASE2
Sponsor
Inhye Ahn
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Mosunetuzumab
  • Ibrutinib
  • Acalabrutinib
  • Zanubrutinib
  • Pirtobrutinib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Meet 2018 iwCLL guidelines for the diagnosis of CLL or SLL
  • Recent completion of treatment or ongoing treatment for CLL/SLL as follows:
  • BTKi arm: On continuous BTKi therapy for \> 12 months, including \> 2 months at a stable dose.
  • BTKis include ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →